Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
University of Southern California
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04616248CT.gov In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bone Sarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Recombinant Flt3 Ligand (this asset) | University of Southern California | P1 | CC · 43 |
| Cyclophosphamide | Essen Biotech | P2 | BB |
| Fludarabine | Essen Biotech | P2 | B |
| Ipilimumab | M.D. Anderson Cancer Center | P2 | CCC |
| Nivolumab | M.D. Anderson Cancer Center | P2 | CCC |
| Lifileucel | M.D. Anderson Cancer Center | P2 | CCC |
| Teonanacatl | University Health Network, Toronto | P2 | CCC |
| cd146/her2 car-t cells | Essen Biotech | P1/2 | CCC |
| Opa-Interacting Protein 4 | Mannkind Corporation | P1 | CC |
+4 more in the Bone Sarcoma cohort
Other indications for Recombinant Flt3 Ligand
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cutaneous Melanoma | — | P2 | B · 61 |
| Leukemia | — | P3 | B · 59 |
| Mucosal Melanoma | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Recombinant Flt3 Ligand in Bone Sarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/recombinant-flt3-ligand-bone-sarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →